A booster given six months after the second dose of the vaccine increases the potency of antibodies against the original virus and the beta variant by five- to tenfold, Pfizer and BioNTech said
A member of the U.S. military and an employee of the New Jersey Institute of Technology prepared doses of the Pfizer-BioNTech COVID-19 vaccine at an immunization site in Newark, N.J., June 19, 2021. The Delta variant of the coronavirus can evade antibodies that target certain parts of the virus, according to a new study published on Thursday, July 8, 2021, in Nature.
Pfizer and BioNTech announced Thursday that they were developing a version of the coronavirus vaccine that targets delta, a highly contagious variant that has spread to nearly 100 countries. The companies expect to begin clinical trials of the vaccine in August.
©2019 New York Times News Service